Five financial analysts have provided diverse ratings for Globus Medical (NYSE:GMED) over the last three months, with recent updates showing a mix of bullish and indifferent stances. The average 12-month price target for GMED has increased to $67.6, with a high estimate of $86.00 and a low of $53.00. Analysts from Canaccord Genuity, Morgan Stanley, Truist Securities, Roth MKM, and Barclays have adjusted their ratings and price targets, reflecting their latest views on the company's performance and market conditions. Globus Medical, a medical device company, has seen significant revenue growth but faces challenges with net margin, ROE, and ROA below industry standards, despite a conservative debt management approach.